. Author manuscript; available in PMC: 2009 Jan 7.

Published in final edited form as: J Nucl Med. 2008 Sep 15;49(10):1613–1619. doi: 10.2967/jnumed.108.052373

Table 3.

Results and comparisons among functional imaging modalities by patient and by region (left adrenal gland, right adrenal gland, liver, abdominal/pelvic compartment (excluding adrenal glands and liver), lungs, mediastinum, neck and bone (including head and/or skull)) in those studied with [¹⁸F]-DA PET, [¹²³I]-MIBG scintigraphy and SRS.

Non-metastatic PHEO (n=5)
Functional imaging modality	(+) patient studies:	(+) regions:
[¹⁸F]-DA	5	6
[¹²³I]-MIBG	5	5
SRS	1	1

Metastatic PHEO (n=15)

Functional imaging modality	(+) patient studies:	(+) regions:

[¹⁸F]-DA	14	31
[¹²³I]-MIBG	10	31
SRS	15	44